CD274 and gastric cancer: These observations highlight the complex interplay between PD-L1 expression and other immunotherapy biomarkers in gastric cancer, emphasizing the need for comprehensive biomarker profiling rather than reliance on PD-L1 expression alone for treatment stratification.